Novartis has announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. The new site is part of the company’s previously announced $23 billion investment in US infrastructure over the next five years. The facility,
Novartis has built up substantial pharmaceutical stockpiles in the United States and announced major manufacturing investments as the Swiss company prepares for potential tariffs under President Trump’s trade policies, CEO Vas Narasimhan revealed on Saturday. Speaking to Swiss newspaper Neue
Novartis has announced an expansion of its biologics manufacturing infrastructure in Austria, with a new cell culture system under construction at its Kundl Drug Substance site. The facility, known as RPP1-CC, is expected to be GMP-ready by the third quarter of
Novartis has officially opened a €40 million ($41.2 million) viral vector manufacturing facility in Mengeš, Slovenia, as part of its broader strategy to enhance cell and gene therapy capabilities across Europe. The site, named VIFA One, represents the company’s first
Novartis has announced a significant expansion of its biopharmaceutical manufacturing site in Singapore. The company is investing US$256 million to enhance its manufacturing productivity, improve operational efficiency, and upskill its workforce. The expansion is a strategic move to address the ‘soaring
Rathish Ravindrakumar explains the services the CDMO offers and the importance of sustainability to the pharma supply chain.
Mark Burfoot, VP Research Procurement at Novartis explains how advances in Machine Learning allow procurement to have a more strategic role in optimising life science research.
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
